Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.

Abstract

OBJECTIVES: The effects of atorvastatin, a new synthetic HMG-CoA reductase inhibitor, were investigated in patients with familial hypercholesterolaemia (FH), with high LDLc levels whilst on standard treatment. DESIGN: Open treatment with 40 mg atorvastatin daily for 6 weeks, followed by another 6 weeks with 80 mg atorvastatin. SETTING: Outpatient lipid clinic of a tertiary referral centre. SUBJECTS: FH was diagnosed when the untreated LDLc concentration was higher than 6 mmol L-1, tendon xanthomas were present at the participant or a first degree relative, and the family history for hypercholesterolaemia was positive. The FH patients were selected for an LDLc above 5.0 mmol L-1 whilst on standard therapy for at least 3 months. Standard therapy consisted of a diet and 40 mg simvastatin, either alone (n = 17), or in combination with 8-12 g colestyramin (n = 12), or 1800 mg nicotinic acid (n = 12). MAIN OUTCOME MEASURE: Effects on LDLc concentration. RESULTS: LDLc concentration significantly decreased during treatment with 80 mg atorvastatin as compared to LDLc levels on 40 mg simvastatin alone or in combination with 8-12 g colestyramin, by 24 +/- 14% (P < 0.01) and 19 +/- 22% (P < 0.01), respectively. LDLc concentration was comparable during treatment with 80 mg atorvastatin or 40 mg simvastatin in combination with 1800 mg nicotinic acid. Atorvastatin was tolerated well, no side-effects were observed. CONCLUSIONS: Atorvastatin is a valuable addition to the treatment possibilities of patients with serious hypercholesterolaemia, like FH.